Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lenses, Intraocular | 12 | 2023 | 140 | 6.010 |
Why?
|
Corneal Diseases | 24 | 2023 | 635 | 4.770 |
Why?
|
Lens Implantation, Intraocular | 14 | 2023 | 192 | 4.380 |
Why?
|
Keratoconus | 11 | 2023 | 121 | 3.960 |
Why?
|
Cornea | 31 | 2023 | 1521 | 3.900 |
Why?
|
Corneal Transplantation | 13 | 2022 | 384 | 3.780 |
Why?
|
Descemet Membrane | 7 | 2021 | 72 | 3.410 |
Why?
|
Fuchs' Endothelial Dystrophy | 6 | 2021 | 84 | 3.120 |
Why?
|
Descemet Stripping Endothelial Keratoplasty | 10 | 2022 | 107 | 2.890 |
Why?
|
Phacoemulsification | 9 | 2020 | 148 | 2.580 |
Why?
|
Keratomileusis, Laser In Situ | 10 | 2014 | 88 | 2.520 |
Why?
|
Cataract | 11 | 2023 | 834 | 2.470 |
Why?
|
Sclera | 6 | 2021 | 200 | 2.290 |
Why?
|
Visual Acuity | 32 | 2023 | 2525 | 2.090 |
Why?
|
Refraction, Ocular | 5 | 2019 | 181 | 2.010 |
Why?
|
Astigmatism | 8 | 2019 | 68 | 2.000 |
Why?
|
Cataract Extraction | 10 | 2023 | 481 | 1.900 |
Why?
|
Mucopolysaccharidosis I | 4 | 2022 | 50 | 1.660 |
Why?
|
Corneal Topography | 10 | 2023 | 69 | 1.640 |
Why?
|
Erythema | 2 | 2023 | 257 | 1.630 |
Why?
|
Iris | 6 | 2023 | 239 | 1.550 |
Why?
|
Corneal Ulcer | 7 | 2023 | 169 | 1.500 |
Why?
|
Trigeminal Nerve Diseases | 2 | 2021 | 55 | 1.500 |
Why?
|
Prostheses and Implants | 9 | 2022 | 1385 | 1.400 |
Why?
|
Refractive Surgical Procedures | 3 | 2019 | 25 | 1.400 |
Why?
|
Nerve Transfer | 2 | 2021 | 120 | 1.390 |
Why?
|
Eye | 2 | 2023 | 727 | 1.340 |
Why?
|
Corneal Edema | 4 | 2020 | 51 | 1.270 |
Why?
|
Artificial Organs | 4 | 2016 | 204 | 1.230 |
Why?
|
Lasers, Excimer | 6 | 2015 | 72 | 1.230 |
Why?
|
Eye Diseases | 3 | 2023 | 668 | 1.200 |
Why?
|
Anterior Eye Segment | 4 | 2012 | 152 | 1.170 |
Why?
|
Corneal Opacity | 4 | 2015 | 60 | 1.150 |
Why?
|
Myopia | 9 | 2010 | 253 | 1.090 |
Why?
|
Keratitis | 6 | 2012 | 268 | 1.070 |
Why?
|
Hyperopia | 3 | 2019 | 44 | 1.070 |
Why?
|
Eye Infections, Fungal | 5 | 2014 | 110 | 1.050 |
Why?
|
Lens Subluxation | 2 | 2016 | 20 | 1.020 |
Why?
|
Ophthalmology | 5 | 2023 | 508 | 0.980 |
Why?
|
Coloboma | 2 | 2023 | 54 | 0.970 |
Why?
|
Presbyopia | 2 | 2016 | 9 | 0.950 |
Why?
|
Eye Infections, Bacterial | 6 | 2014 | 235 | 0.950 |
Why?
|
Corneal Stroma | 6 | 2020 | 174 | 0.920 |
Why?
|
Pseudophakia | 3 | 2021 | 62 | 0.910 |
Why?
|
Corneal Wavefront Aberration | 2 | 2013 | 6 | 0.890 |
Why?
|
Aberrometry | 2 | 2013 | 6 | 0.890 |
Why?
|
Iris Diseases | 1 | 2023 | 40 | 0.870 |
Why?
|
Smallpox | 1 | 2023 | 45 | 0.870 |
Why?
|
Mucopolysaccharidoses | 2 | 2022 | 27 | 0.860 |
Why?
|
Postoperative Complications | 15 | 2021 | 15281 | 0.860 |
Why?
|
Vaccinia | 1 | 2023 | 76 | 0.850 |
Why?
|
Suture Techniques | 6 | 2021 | 797 | 0.820 |
Why?
|
Vision Disorders | 6 | 2016 | 1055 | 0.800 |
Why?
|
beta-Alanine | 1 | 2021 | 74 | 0.770 |
Why?
|
Eye Injuries | 5 | 2023 | 244 | 0.760 |
Why?
|
Intraoperative Complications | 3 | 2017 | 1195 | 0.730 |
Why?
|
Photorefractive Keratectomy | 3 | 2008 | 38 | 0.730 |
Why?
|
Contact Lenses | 2 | 2012 | 145 | 0.730 |
Why?
|
Endothelium, Corneal | 4 | 2020 | 197 | 0.720 |
Why?
|
Benzoates | 1 | 2021 | 218 | 0.700 |
Why?
|
Sutures | 2 | 2021 | 299 | 0.680 |
Why?
|
Eye Abnormalities | 2 | 2013 | 246 | 0.670 |
Why?
|
Prosthesis Implantation | 6 | 2016 | 640 | 0.650 |
Why?
|
Nausea | 1 | 2021 | 674 | 0.630 |
Why?
|
Uveal Neoplasms | 2 | 2017 | 310 | 0.610 |
Why?
|
Aphakia, Postcataract | 1 | 2017 | 54 | 0.600 |
Why?
|
Retinal Dystrophies | 1 | 2017 | 58 | 0.580 |
Why?
|
Ectopia Lentis | 1 | 2016 | 20 | 0.570 |
Why?
|
Keratoplasty, Penetrating | 7 | 2022 | 155 | 0.560 |
Why?
|
Prosthesis-Related Infections | 2 | 2012 | 537 | 0.550 |
Why?
|
Fluoroquinolones | 3 | 2011 | 308 | 0.540 |
Why?
|
Lens, Crystalline | 4 | 2016 | 388 | 0.530 |
Why?
|
Uveitis, Anterior | 2 | 2023 | 101 | 0.530 |
Why?
|
Lens Capsule, Crystalline | 2 | 2013 | 43 | 0.520 |
Why?
|
Eyeglasses | 1 | 2016 | 141 | 0.510 |
Why?
|
Tomography, Optical Coherence | 4 | 2023 | 2657 | 0.510 |
Why?
|
Iridectomy | 1 | 2015 | 49 | 0.510 |
Why?
|
Anterior Chamber | 4 | 2022 | 197 | 0.500 |
Why?
|
Uveitis | 2 | 2023 | 374 | 0.500 |
Why?
|
Photophobia | 1 | 2015 | 67 | 0.490 |
Why?
|
Copper | 1 | 2017 | 366 | 0.480 |
Why?
|
Elastic Modulus | 6 | 2019 | 214 | 0.480 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2019 | 717 | 0.470 |
Why?
|
Blindness | 2 | 2015 | 612 | 0.460 |
Why?
|
Headache | 1 | 2021 | 1224 | 0.450 |
Why?
|
Humans | 114 | 2023 | 743811 | 0.450 |
Why?
|
Posterior Eye Segment | 1 | 2013 | 14 | 0.450 |
Why?
|
Endophthalmitis | 2 | 2014 | 262 | 0.440 |
Why?
|
Corneal Surgery, Laser | 1 | 2012 | 11 | 0.440 |
Why?
|
Cosmetic Techniques | 2 | 2012 | 135 | 0.440 |
Why?
|
Optics and Photonics | 1 | 2014 | 319 | 0.430 |
Why?
|
Coloring Agents | 1 | 2015 | 565 | 0.430 |
Why?
|
Alcaligenes | 1 | 2011 | 1 | 0.420 |
Why?
|
Glaucoma | 3 | 2022 | 1158 | 0.410 |
Why?
|
Conjunctiva | 4 | 2011 | 494 | 0.390 |
Why?
|
Accommodation, Ocular | 2 | 2016 | 48 | 0.390 |
Why?
|
Lasers, Solid-State | 2 | 2010 | 169 | 0.380 |
Why?
|
Graft Survival | 3 | 2020 | 3734 | 0.380 |
Why?
|
Aspergillosis | 1 | 2012 | 235 | 0.370 |
Why?
|
Gram-Negative Bacterial Infections | 2 | 2011 | 232 | 0.370 |
Why?
|
Keratotomy, Radial | 1 | 2009 | 5 | 0.370 |
Why?
|
Physical Examination | 1 | 2016 | 1235 | 0.370 |
Why?
|
Glaucoma, Angle-Closure | 1 | 2012 | 189 | 0.360 |
Why?
|
Anesthesia | 1 | 2021 | 1562 | 0.360 |
Why?
|
Ocular Hypertension | 2 | 2008 | 198 | 0.360 |
Why?
|
Prosthesis Fitting | 1 | 2010 | 74 | 0.350 |
Why?
|
Dry Eye Syndromes | 1 | 2014 | 386 | 0.350 |
Why?
|
Acanthamoeba Keratitis | 2 | 2007 | 17 | 0.340 |
Why?
|
Sensation Disorders | 1 | 2010 | 156 | 0.330 |
Why?
|
Cell Count | 3 | 2020 | 1855 | 0.330 |
Why?
|
Keratitis, Herpetic | 1 | 2009 | 81 | 0.330 |
Why?
|
Ketorolac Tromethamine | 2 | 2006 | 21 | 0.320 |
Why?
|
Mycobacterium chelonae | 1 | 2007 | 11 | 0.310 |
Why?
|
Virus Activation | 1 | 2009 | 319 | 0.300 |
Why?
|
Epithelium, Corneal | 3 | 2023 | 247 | 0.300 |
Why?
|
Ophthalmic Solutions | 4 | 2021 | 316 | 0.290 |
Why?
|
Retrospective Studies | 23 | 2023 | 77410 | 0.290 |
Why?
|
Scleritis | 1 | 2007 | 100 | 0.290 |
Why?
|
Iatrogenic Disease | 1 | 2009 | 546 | 0.280 |
Why?
|
Wounds, Nonpenetrating | 1 | 2013 | 795 | 0.270 |
Why?
|
Prednisolone | 5 | 2009 | 334 | 0.270 |
Why?
|
Developing Countries | 3 | 2015 | 2815 | 0.270 |
Why?
|
Monkeypox virus | 2 | 2023 | 48 | 0.270 |
Why?
|
Drug Resistance, Bacterial | 3 | 2008 | 1030 | 0.260 |
Why?
|
Reoperation | 4 | 2020 | 4200 | 0.250 |
Why?
|
Protein Kinase Inhibitors | 1 | 2021 | 5532 | 0.250 |
Why?
|
Middle Aged | 32 | 2021 | 213241 | 0.240 |
Why?
|
Optic Nerve Diseases | 1 | 2008 | 327 | 0.240 |
Why?
|
Male | 41 | 2023 | 349776 | 0.240 |
Why?
|
Herpesvirus 1, Human | 1 | 2009 | 743 | 0.230 |
Why?
|
Eye Infections | 1 | 2004 | 64 | 0.230 |
Why?
|
Mass Screening | 1 | 2019 | 5251 | 0.230 |
Why?
|
Capsulorhexis | 1 | 2023 | 15 | 0.230 |
Why?
|
Postoperative Care | 1 | 2010 | 1485 | 0.220 |
Why?
|
Abnormalities, Multiple | 1 | 2010 | 1416 | 0.210 |
Why?
|
Scleral Diseases | 2 | 2002 | 22 | 0.210 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 2 | 2006 | 2281 | 0.210 |
Why?
|
Eye Neoplasms | 3 | 2010 | 312 | 0.200 |
Why?
|
Prosthesis Design | 4 | 2021 | 2103 | 0.200 |
Why?
|
Device Removal | 3 | 2012 | 655 | 0.200 |
Why?
|
Eye Burns | 1 | 2002 | 103 | 0.200 |
Why?
|
Treatment Outcome | 15 | 2022 | 63042 | 0.200 |
Why?
|
Polypropylenes | 1 | 2021 | 64 | 0.200 |
Why?
|
Female | 40 | 2022 | 380020 | 0.200 |
Why?
|
Glaucoma Drainage Implants | 1 | 2022 | 115 | 0.190 |
Why?
|
Microscopy, Confocal | 4 | 2016 | 1962 | 0.190 |
Why?
|
Tonometry, Ocular | 1 | 2021 | 237 | 0.190 |
Why?
|
Keratoconjunctivitis | 2 | 1998 | 53 | 0.180 |
Why?
|
Lacerations | 1 | 2002 | 143 | 0.180 |
Why?
|
Decision Support Techniques | 1 | 2010 | 1956 | 0.180 |
Why?
|
rho-Associated Kinases | 1 | 2021 | 279 | 0.180 |
Why?
|
Drug Therapy, Combination | 5 | 2012 | 6487 | 0.170 |
Why?
|
Intraocular Pressure | 3 | 2022 | 1269 | 0.170 |
Why?
|
Rupture, Spontaneous | 2 | 2013 | 354 | 0.170 |
Why?
|
Aged | 17 | 2021 | 163178 | 0.170 |
Why?
|
Adult | 27 | 2023 | 213889 | 0.170 |
Why?
|
Learning Curve | 1 | 2020 | 208 | 0.160 |
Why?
|
Capsule Opacification | 1 | 2017 | 2 | 0.160 |
Why?
|
Ciliary Body | 2 | 1997 | 173 | 0.160 |
Why?
|
Anti-Bacterial Agents | 5 | 2011 | 7172 | 0.150 |
Why?
|
Surgical Wound Infection | 1 | 2007 | 1539 | 0.150 |
Why?
|
Adenovirus Infections, Human | 1 | 1998 | 71 | 0.150 |
Why?
|
Anesthesia, Local | 1 | 2000 | 275 | 0.150 |
Why?
|
Eye Infections, Viral | 1 | 1998 | 57 | 0.150 |
Why?
|
Models, Theoretical | 1 | 2010 | 3587 | 0.150 |
Why?
|
Spectrum Analysis | 1 | 2019 | 454 | 0.150 |
Why?
|
Acute Disease | 2 | 2021 | 7150 | 0.150 |
Why?
|
Diagnostic Techniques, Ophthalmological | 1 | 2019 | 245 | 0.140 |
Why?
|
Health Care Costs | 1 | 2010 | 3207 | 0.140 |
Why?
|
Choroid Neoplasms | 1 | 1998 | 175 | 0.140 |
Why?
|
Hot Temperature | 1 | 2002 | 1351 | 0.140 |
Why?
|
Burns, Chemical | 1 | 2018 | 159 | 0.140 |
Why?
|
Adjuvants, Pharmaceutic | 1 | 1996 | 50 | 0.140 |
Why?
|
Drug Implants | 1 | 2016 | 241 | 0.130 |
Why?
|
Elasticity | 2 | 2015 | 657 | 0.130 |
Why?
|
Glare | 1 | 2015 | 8 | 0.130 |
Why?
|
Glaucoma, Open-Angle | 2 | 2021 | 705 | 0.130 |
Why?
|
Intravitreal Injections | 1 | 2016 | 344 | 0.130 |
Why?
|
Cysts | 1 | 2020 | 678 | 0.130 |
Why?
|
Patient Satisfaction | 2 | 2018 | 3391 | 0.130 |
Why?
|
Wounds, Penetrating | 1 | 1997 | 307 | 0.130 |
Why?
|
Homosexuality, Male | 1 | 2023 | 1240 | 0.130 |
Why?
|
Axial Length, Eye | 1 | 2014 | 31 | 0.130 |
Why?
|
Pigmentation | 1 | 2015 | 148 | 0.120 |
Why?
|
Antibiotic Prophylaxis | 2 | 2014 | 638 | 0.120 |
Why?
|
Retinal Diseases | 2 | 2018 | 685 | 0.120 |
Why?
|
Melanoma, Experimental | 1 | 1998 | 560 | 0.120 |
Why?
|
Air | 2 | 2013 | 182 | 0.120 |
Why?
|
Follow-Up Studies | 8 | 2022 | 39001 | 0.120 |
Why?
|
Bioartificial Organs | 1 | 2014 | 49 | 0.120 |
Why?
|
Vitrectomy | 1 | 2016 | 365 | 0.110 |
Why?
|
Crystallins | 1 | 1993 | 75 | 0.110 |
Why?
|
Cogan Syndrome | 1 | 2013 | 11 | 0.110 |
Why?
|
Disease Outbreaks | 1 | 2023 | 1771 | 0.110 |
Why?
|
Endotamponade | 1 | 2013 | 35 | 0.110 |
Why?
|
Collagen | 2 | 2013 | 2681 | 0.110 |
Why?
|
Blepharitis | 2 | 2005 | 36 | 0.110 |
Why?
|
Trichosporon | 1 | 2012 | 8 | 0.110 |
Why?
|
Silicone Elastomers | 1 | 2012 | 83 | 0.110 |
Why?
|
Lacrimal Apparatus | 1 | 2014 | 225 | 0.110 |
Why?
|
Corneal Endothelial Cell Loss | 1 | 2012 | 24 | 0.110 |
Why?
|
Apraxias | 1 | 2013 | 63 | 0.110 |
Why?
|
Lupus Erythematosus, Discoid | 2 | 2005 | 49 | 0.100 |
Why?
|
Aza Compounds | 1 | 2011 | 32 | 0.100 |
Why?
|
Standard of Care | 1 | 2016 | 564 | 0.100 |
Why?
|
Microbial Sensitivity Tests | 3 | 2008 | 1870 | 0.100 |
Why?
|
Intraoperative Period | 1 | 2012 | 520 | 0.100 |
Why?
|
Tissue Donors | 1 | 2021 | 2241 | 0.100 |
Why?
|
Refractive Errors | 1 | 2013 | 141 | 0.100 |
Why?
|
Wound Healing | 1 | 2002 | 2776 | 0.100 |
Why?
|
Conjunctivitis | 2 | 2005 | 158 | 0.100 |
Why?
|
Biometry | 1 | 2014 | 558 | 0.100 |
Why?
|
Ophthalmologic Surgical Procedures | 2 | 2007 | 349 | 0.100 |
Why?
|
Aspergillus fumigatus | 1 | 2012 | 150 | 0.100 |
Why?
|
Pilot Projects | 2 | 2021 | 8316 | 0.100 |
Why?
|
Cross-Linking Reagents | 2 | 2013 | 694 | 0.100 |
Why?
|
Immunoenzyme Techniques | 2 | 2010 | 1799 | 0.090 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2016 | 789 | 0.090 |
Why?
|
Diagnostic Tests, Routine | 1 | 2016 | 782 | 0.090 |
Why?
|
Sudan | 1 | 2010 | 83 | 0.090 |
Why?
|
Stromal Cells | 1 | 2016 | 1356 | 0.090 |
Why?
|
Retinoblastoma | 1 | 1993 | 316 | 0.090 |
Why?
|
Polymethyl Methacrylate | 1 | 2011 | 145 | 0.090 |
Why?
|
Glucocorticoids | 3 | 2009 | 2107 | 0.090 |
Why?
|
Microscopy | 2 | 2020 | 896 | 0.090 |
Why?
|
Program Development | 1 | 2016 | 1314 | 0.090 |
Why?
|
Curriculum | 1 | 2023 | 3603 | 0.090 |
Why?
|
Antifungal Agents | 2 | 2012 | 729 | 0.090 |
Why?
|
Goldenhar Syndrome | 1 | 2010 | 37 | 0.090 |
Why?
|
Epithelial Cells | 1 | 2002 | 3690 | 0.090 |
Why?
|
Neurilemmoma | 1 | 1995 | 547 | 0.090 |
Why?
|
Vimentin | 1 | 2010 | 262 | 0.090 |
Why?
|
Autoimmune Diseases | 1 | 2021 | 2134 | 0.090 |
Why?
|
Elasticity Imaging Techniques | 1 | 2014 | 388 | 0.090 |
Why?
|
Retina | 2 | 2018 | 2612 | 0.080 |
Why?
|
Visually Impaired Persons | 1 | 2010 | 79 | 0.080 |
Why?
|
Anti-Inflammatory Agents | 3 | 2018 | 1789 | 0.080 |
Why?
|
Dermoid Cyst | 1 | 2010 | 93 | 0.080 |
Why?
|
Finland | 1 | 2010 | 602 | 0.080 |
Why?
|
Mycoses | 2 | 2007 | 376 | 0.080 |
Why?
|
Sickness Impact Profile | 1 | 2010 | 302 | 0.080 |
Why?
|
Keratins | 1 | 2010 | 515 | 0.080 |
Why?
|
Acyclovir | 1 | 2009 | 272 | 0.080 |
Why?
|
Titanium | 1 | 2011 | 487 | 0.080 |
Why?
|
Surgical Flaps | 2 | 2007 | 1629 | 0.080 |
Why?
|
Ethiopia | 1 | 2010 | 495 | 0.080 |
Why?
|
Graft Rejection | 1 | 2021 | 4398 | 0.080 |
Why?
|
Biguanides | 1 | 2007 | 23 | 0.080 |
Why?
|
Benzamidines | 1 | 2007 | 25 | 0.080 |
Why?
|
Chloramphenicol | 1 | 2007 | 75 | 0.080 |
Why?
|
Education, Medical, Graduate | 1 | 2020 | 2291 | 0.080 |
Why?
|
Alternaria | 1 | 2007 | 44 | 0.080 |
Why?
|
Eyelids | 1 | 2010 | 264 | 0.080 |
Why?
|
Aniridia | 1 | 2007 | 37 | 0.070 |
Why?
|
Postoperative Period | 1 | 2012 | 1841 | 0.070 |
Why?
|
Aged, 80 and over | 5 | 2021 | 57744 | 0.070 |
Why?
|
Corneal Neovascularization | 1 | 2009 | 188 | 0.070 |
Why?
|
Clarithromycin | 1 | 2007 | 86 | 0.070 |
Why?
|
Patient Selection | 1 | 2019 | 4210 | 0.070 |
Why?
|
Papilledema | 1 | 2008 | 118 | 0.070 |
Why?
|
Quinolines | 1 | 2011 | 732 | 0.070 |
Why?
|
Photosensitizing Agents | 1 | 2010 | 602 | 0.070 |
Why?
|
Models, Economic | 1 | 2010 | 712 | 0.070 |
Why?
|
India | 1 | 2012 | 2200 | 0.070 |
Why?
|
Disease Management | 1 | 2016 | 2459 | 0.070 |
Why?
|
Body Weights and Measures | 1 | 2006 | 211 | 0.070 |
Why?
|
Ultraviolet Rays | 1 | 2010 | 1060 | 0.070 |
Why?
|
Transplantation, Autologous | 1 | 2010 | 2123 | 0.060 |
Why?
|
Costs and Cost Analysis | 1 | 2010 | 1680 | 0.060 |
Why?
|
Prospective Studies | 4 | 2021 | 53250 | 0.060 |
Why?
|
Photochemotherapy | 1 | 2010 | 808 | 0.060 |
Why?
|
Quality-Adjusted Life Years | 1 | 2010 | 1683 | 0.060 |
Why?
|
Syndrome | 1 | 2010 | 3249 | 0.060 |
Why?
|
Disease Models, Animal | 3 | 2013 | 18027 | 0.060 |
Why?
|
Electrocoagulation | 1 | 2004 | 158 | 0.060 |
Why?
|
Isoindoles | 1 | 2022 | 41 | 0.050 |
Why?
|
Trifluridine | 1 | 2022 | 29 | 0.050 |
Why?
|
Health Care Surveys | 1 | 2010 | 2453 | 0.050 |
Why?
|
Health Services Research | 1 | 2010 | 1836 | 0.050 |
Why?
|
Antiviral Agents | 2 | 2009 | 2984 | 0.050 |
Why?
|
Adolescent | 6 | 2016 | 85729 | 0.050 |
Why?
|
Down Syndrome | 1 | 2010 | 880 | 0.050 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2016 | 5170 | 0.050 |
Why?
|
Activities of Daily Living | 1 | 2010 | 2419 | 0.050 |
Why?
|
Retrobulbar Hemorrhage | 1 | 2000 | 11 | 0.050 |
Why?
|
Eye Injuries, Penetrating | 1 | 2002 | 114 | 0.050 |
Why?
|
Child, Preschool | 5 | 2010 | 40964 | 0.050 |
Why?
|
Anti-Infective Agents | 1 | 2007 | 971 | 0.040 |
Why?
|
Disease Progression | 2 | 2014 | 13273 | 0.040 |
Why?
|
Aging | 2 | 2016 | 8655 | 0.040 |
Why?
|
Fundus Oculi | 2 | 1998 | 473 | 0.040 |
Why?
|
Stress, Mechanical | 2 | 2016 | 1684 | 0.040 |
Why?
|
Angiogenesis Inhibitors | 1 | 2009 | 2037 | 0.040 |
Why?
|
Prognosis | 3 | 2007 | 29052 | 0.040 |
Why?
|
Ultrasonography | 2 | 2006 | 5986 | 0.040 |
Why?
|
Optic Nerve Injuries | 1 | 2000 | 150 | 0.040 |
Why?
|
Sclerostomy | 1 | 1998 | 15 | 0.040 |
Why?
|
Combined Modality Therapy | 2 | 2007 | 8637 | 0.040 |
Why?
|
Tolmetin | 1 | 1997 | 23 | 0.040 |
Why?
|
Tromethamine | 1 | 1997 | 31 | 0.040 |
Why?
|
Child | 6 | 2020 | 77637 | 0.040 |
Why?
|
Occlusive Dressings | 1 | 1997 | 50 | 0.040 |
Why?
|
Carbonic Anhydrase Inhibitors | 1 | 2018 | 94 | 0.040 |
Why?
|
Tumor Cells, Cultured | 2 | 1998 | 6311 | 0.040 |
Why?
|
Cost-Benefit Analysis | 1 | 2010 | 5388 | 0.040 |
Why?
|
Benzamides | 1 | 2023 | 1383 | 0.040 |
Why?
|
Amyloid beta-Peptides | 1 | 2010 | 3587 | 0.040 |
Why?
|
Laser Therapy | 1 | 2004 | 1071 | 0.040 |
Why?
|
Injections | 1 | 2000 | 839 | 0.040 |
Why?
|
Ultrasonography, Doppler, Color | 1 | 1998 | 233 | 0.040 |
Why?
|
Risk Factors | 3 | 2022 | 72252 | 0.040 |
Why?
|
Orbit | 1 | 2000 | 426 | 0.040 |
Why?
|
Fluorescein Angiography | 2 | 1998 | 940 | 0.030 |
Why?
|
Oculomotor Muscles | 1 | 2000 | 370 | 0.030 |
Why?
|
ROC Curve | 1 | 2023 | 3527 | 0.030 |
Why?
|
History, 20th Century | 1 | 2004 | 2736 | 0.030 |
Why?
|
Phlebitis | 1 | 1995 | 31 | 0.030 |
Why?
|
Incidence | 4 | 2022 | 20948 | 0.030 |
Why?
|
Retinal Vein | 1 | 1995 | 47 | 0.030 |
Why?
|
Imaging, Three-Dimensional | 3 | 2014 | 4033 | 0.030 |
Why?
|
Central Nervous System Diseases | 1 | 2000 | 518 | 0.030 |
Why?
|
Gonioscopy | 1 | 1995 | 157 | 0.030 |
Why?
|
United States | 4 | 2022 | 69859 | 0.030 |
Why?
|
Tissue Culture Techniques | 1 | 2016 | 291 | 0.030 |
Why?
|
Rabbits | 2 | 1998 | 4894 | 0.030 |
Why?
|
Pressure | 1 | 1997 | 1205 | 0.030 |
Why?
|
Administration, Topical | 2 | 2009 | 689 | 0.030 |
Why?
|
Paraneoplastic Syndromes | 1 | 1995 | 151 | 0.030 |
Why?
|
Infant | 4 | 2010 | 35122 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2006 | 10940 | 0.030 |
Why?
|
Anesthetics, Local | 1 | 2000 | 985 | 0.030 |
Why?
|
Antineoplastic Agents | 1 | 2016 | 13691 | 0.030 |
Why?
|
Pigmentation Disorders | 1 | 1992 | 101 | 0.030 |
Why?
|
Antibodies, Monoclonal | 1 | 2009 | 9272 | 0.030 |
Why?
|
Severity of Illness Index | 1 | 2009 | 15526 | 0.030 |
Why?
|
Microscopy, Electron | 1 | 1995 | 2646 | 0.030 |
Why?
|
Macaca | 1 | 1993 | 439 | 0.020 |
Why?
|
Lung Neoplasms | 1 | 2016 | 13112 | 0.020 |
Why?
|
Blotting, Northern | 1 | 1993 | 1581 | 0.020 |
Why?
|
Neuroprotective Agents | 1 | 2018 | 941 | 0.020 |
Why?
|
Animals | 8 | 2016 | 168660 | 0.020 |
Why?
|
Fibrosis | 1 | 1998 | 2030 | 0.020 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2016 | 713 | 0.020 |
Why?
|
Demography | 1 | 2015 | 1653 | 0.020 |
Why?
|
Riboflavin | 1 | 2010 | 108 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 1998 | 3617 | 0.020 |
Why?
|
China | 1 | 2015 | 2243 | 0.020 |
Why?
|
Alzheimer Disease | 1 | 2010 | 8035 | 0.020 |
Why?
|
Protein Structure, Quaternary | 1 | 2010 | 436 | 0.020 |
Why?
|
Epinephrine | 1 | 1992 | 792 | 0.020 |
Why?
|
Hydroxychloroquine | 2 | 2005 | 412 | 0.020 |
Why?
|
Steroids | 1 | 1994 | 930 | 0.020 |
Why?
|
Scattering, Radiation | 1 | 2010 | 497 | 0.020 |
Why?
|
Polymyxin B | 1 | 2007 | 46 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2016 | 3547 | 0.020 |
Why?
|
Ofloxacin | 1 | 2007 | 65 | 0.020 |
Why?
|
Itraconazole | 1 | 2007 | 43 | 0.020 |
Why?
|
Trimethoprim | 1 | 2007 | 91 | 0.020 |
Why?
|
Cefazolin | 1 | 2008 | 96 | 0.020 |
Why?
|
Practice Guidelines as Topic | 1 | 2005 | 7270 | 0.020 |
Why?
|
Amphotericin B | 1 | 2007 | 137 | 0.020 |
Why?
|
Biopsy | 2 | 1999 | 6750 | 0.020 |
Why?
|
Gentamicins | 1 | 2008 | 255 | 0.020 |
Why?
|
Eye Proteins | 1 | 2010 | 645 | 0.020 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2018 | 4422 | 0.020 |
Why?
|
Ciprofloxacin | 1 | 2008 | 314 | 0.020 |
Why?
|
Cattle | 1 | 2012 | 3917 | 0.020 |
Why?
|
Case-Control Studies | 1 | 2023 | 21733 | 0.020 |
Why?
|
Gram-Positive Bacterial Infections | 1 | 2008 | 340 | 0.020 |
Why?
|
Debridement | 1 | 2007 | 492 | 0.020 |
Why?
|
Prevalence | 1 | 2021 | 15211 | 0.020 |
Why?
|
Reproducibility of Results | 2 | 2013 | 19894 | 0.010 |
Why?
|
Radiography | 1 | 1995 | 7010 | 0.010 |
Why?
|
Light | 1 | 2010 | 1365 | 0.010 |
Why?
|
Tumor Microenvironment | 1 | 2016 | 3583 | 0.010 |
Why?
|
Brain | 1 | 2010 | 26345 | 0.010 |
Why?
|
Double-Blind Method | 1 | 1997 | 12020 | 0.010 |
Why?
|
Cytokines | 1 | 2018 | 7324 | 0.010 |
Why?
|
Swine | 1 | 2013 | 5909 | 0.010 |
Why?
|
Time Factors | 4 | 2011 | 40038 | 0.010 |
Why?
|
Young Adult | 3 | 2016 | 56392 | 0.010 |
Why?
|
Drug Combinations | 1 | 2007 | 1958 | 0.010 |
Why?
|
Pain | 1 | 1997 | 4987 | 0.010 |
Why?
|
Transplantation, Homologous | 1 | 2010 | 4777 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2015 | 12243 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2016 | 11036 | 0.010 |
Why?
|
Bone Marrow Transplantation | 1 | 1989 | 2764 | 0.010 |
Why?
|
Electroretinography | 2 | 1995 | 509 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2021 | 25032 | 0.010 |
Why?
|
Rupture | 1 | 2002 | 433 | 0.010 |
Why?
|
Logistic Models | 1 | 2015 | 13404 | 0.010 |
Why?
|
Gene Expression | 1 | 1993 | 7793 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 1998 | 21824 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 2 | 1997 | 35409 | 0.010 |
Why?
|
Mice | 2 | 1998 | 81154 | 0.010 |
Why?
|
Phenotype | 1 | 2016 | 16361 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 2010 | 13809 | 0.010 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2009 | 3510 | 0.010 |
Why?
|
RNA, Messenger | 1 | 1993 | 13028 | 0.010 |
Why?
|
Chronic Disease | 2 | 2005 | 9139 | 0.010 |
Why?
|
Hypertrophy | 1 | 1999 | 569 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2010 | 18107 | 0.010 |
Why?
|
Melanoma | 1 | 1995 | 5508 | 0.010 |
Why?
|
Radioisotopes | 1 | 1997 | 500 | 0.010 |
Why?
|
Skin Neoplasms | 1 | 1995 | 5691 | 0.010 |
Why?
|
Night Blindness | 1 | 1995 | 53 | 0.010 |
Why?
|
Antirheumatic Agents | 1 | 2005 | 1338 | 0.010 |
Why?
|
Diagnosis, Differential | 2 | 2005 | 12954 | 0.010 |
Why?
|
Forecasting | 1 | 2004 | 2950 | 0.010 |
Why?
|
Retinal Rod Photoreceptor Cells | 1 | 1995 | 195 | 0.010 |
Why?
|
Uveal Diseases | 1 | 1992 | 45 | 0.010 |
Why?
|
Prolapse | 1 | 1992 | 68 | 0.010 |
Why?
|
Gadolinium | 1 | 1997 | 950 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2004 | 7908 | 0.000 |
Why?
|
Image Enhancement | 1 | 1997 | 2915 | 0.000 |
Why?
|
Optic Nerve | 1 | 1989 | 554 | 0.000 |
Why?
|
Edema | 1 | 1989 | 789 | 0.000 |
Why?
|